Skip to Content

Q BioMed Inc QBIO

Morningstar Rating
$0.00 0.00 (50.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

QBIO is trading at a 48% discount.
Price
$0.00
Fair Value
$5.13
Uncertainty
Extreme
1-Star Price
$1.49
5-Star Price
$8.89
Economic Moat
Pdvzp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QBIO is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.02
Bid/Ask
$0.01 / $0.01
Market Cap
$43,528.36
Volume/Avg
1,132 / 109,435

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
7

Valuation

Metric
QBIO
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
QBIO
Quick Ratio
0.00
Current Ratio
0.00
Interest Coverage
0.61
Quick Ratio
QBIO

Profitability

Metric
QBIO
Return on Assets (Normalized)
−3.66%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
QBIO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLhglkrwphHtql$570.1 Bil
VRTX
Vertex Pharmaceuticals IncXmsyzlhtMkmrbc$108.0 Bil
REGN
Regeneron Pharmaceuticals IncTjlyjvcstGsngqn$105.6 Bil
MRNA
Moderna IncPnhgsbqyJpqsd$40.8 Bil
ARGX
argenx SE ADRKxtjqcfShhh$23.5 Bil
BNTX
BioNTech SE ADRHwlrjdjMpm$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncZjgngcpJcfrn$18.8 Bil
BMRN
Biomarin Pharmaceutical IncXxmrhknMqlwqss$16.5 Bil
RPRX
Royalty Pharma PLC Class AZtdglrhxwbBrnstl$13.6 Bil
INCY
Incyte CorpKwfybdwsLbvmbk$12.8 Bil

Sponsor Center